APA (7th ed.) Citation

Lin, M., Weiss, J., Phillips, T. J., Sano, D., Carty, S. A., Wilcox, R., . . . Karimi, Y. H. (2025). Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma. Leukemia & Lymphoma, 66(10), 1850. https://doi.org/10.1080/10428194.2025.2506498

Chicago Style (17th ed.) Citation

Lin, Meng-Hsuan, et al. "Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/refractory Follicular Lymphoma." Leukemia & Lymphoma 66, no. 10 (2025): 1850. https://doi.org/10.1080/10428194.2025.2506498.

MLA (9th ed.) Citation

Lin, Meng-Hsuan, et al. "Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/refractory Follicular Lymphoma." Leukemia & Lymphoma, vol. 66, no. 10, 2025, p. 1850, https://doi.org/10.1080/10428194.2025.2506498.